FDA Expands Bivalent COVID-19 Booster Eligibility for Vulnerable Populations
New Guidance for High-Risk Groups The U.S. Food and Drug Administration (FDA) announced on Tuesday that it has amended its emergency use authorizations for Pfizer-BioNTech and Moderna bivalent COVID-19 vaccines. This regulatory shift allows individuals aged 65 and older, as well as those with compromised immune systems, to receive an additional booster dose ahead of…